Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

10.20 -0.14 (-1.35%)
Streaming Delayed Price Updated: 1:23 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Which stocks are gapping on Wednesday? ↗
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
Omeros Stock Jumps Premarket After FDA Approves First Drug For Rare Transplant Complication — Retail Sees Big Upside ↗
The drug was approved for use in adults and children aged two years and older. 
Via Stocktwits
News headline image
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
From Omeros Corporation
Via Business Wire
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Omeros Stock Garners High Retail Attention Ahead Of FDA Verdict For Life-Saving Drug ↗
The FDA decision on Narsoplimab, its treatment for post–stem cell and bone marrow transplant complications, is officially due on December 26. 
Via Stocktwits
News headline image
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call ↗
Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion. 
Via Stocktwits
Topics Intellectual Property
News headline image
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
From Omeros Corporation
Via Business Wire
News headline image
Omeros (OMER) Q3 2025 Earnings Call Transcript ↗
Omeros (OMER) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Derivatives Earnings
News headline image
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Omeros Corporation Reports Third Quarter 2025 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Examining the Future: Omeros's Earnings Outlook ↗
 
Via Benzinga
News headline image
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
From Omeros Corporation
Via Business Wire
News headline image
Breakout Momentum Plays You Need to Know About ↗
Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential. 
Via MarketBeat
News headline image
4 Biotech Stocks Lifting Off As Momentum Builds ↗
Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels. 
Via Benzinga
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings ↗
 
Via Benzinga
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Unusual volume stocks are being observed in Thursday's session. 
Via Chartmill
News headline image
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
From Omeros Corporation
Via Business Wire
News headline image
Satellogic, Hewlett Packard Enterprise, Bitfarms And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why J.B. Hunt Transport Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? ↗
Find out if the deal Omeros announced is enough of a reason to buy this stock. 
Via The Motley Fool
News headline image
Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside ↗
The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart. 
Via Stocktwits
News headline image
Hims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars Today ↗
Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31. 
Via Benzinga
Topics Stocks
News headline image
The Terrific Ten Undercard: OMER, VERI, SNYR, MYSE, RDZN – Stocks Under $5 (Complete List Inside)
Via AB Newswire
Topics Artificial Intelligence Cannabis
News headline image
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal ↗
Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion and tiered royalties. 
Via Benzinga
News headline image
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results ↗
 
Via Benzinga
News headline image
Omeros Rockets Skyward on $2.1 Billion Novo Nordisk Deal, Reshaping Biotech Landscape
In a dramatic turn of events that sent shockwaves through the biotechnology sector, Omeros Corporation (NASDAQ: OMER) witnessed its stock catapult by an astounding nearly 150% after announcing a... 
Via MarketMinute
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.